Nikhil Khushalani

Stories

HDAC inhibitor plus nivolumab cuts melanoma progression risk by 27% in Phase 3 trial

Presented the Phase 3 results at ESMO Congress 2026

A twice-weekly pill that strips melanoma cells of their camouflage extended progression-free survival by more than four months when added to the standard immunotherapy nivolumab. The Phase 3 result, presented at the European Society for Medical Oncology (ESMO) congress in Madrid, cut the risk of disease progression or death by 27%.

Updated 2 hours ago